---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-003407"
form_type: "8-K/A"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T19:57:34.772597+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics files financials for acquired Old Cartesian and pro forma

## Summary
- Old Cartesian net loss $6.5M in 2022, vs $3.6M in 2021; grant revenue $1.4M in 2022.
- Old Cartesian cash $12.0M at Dec 31, 2022; accumulated deficit $26.1M.
- Unaudited pro forma financials reflect combined entity post-merger closed Nov 13, 2023.

## SEC filing metadata
- accession: 0001140361-24-003407
- form_type: 8-K/A
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000114036124003407/0001140361-24-003407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000114036124003407/ny20014884x4_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-003407
- JSON: https://secwatch.observer/filing/0001140361-24-003407.json
- Plain text: https://secwatch.observer/filing/0001140361-24-003407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.